First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study

Publisher： Karger

E-ISSN： 1423-0232|82|4|218-227

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.4, 2012-04, pp. : 218-227

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer

By  

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-12 ,pp. : 687-692

Karger

Access to resources Recommend Favorite

Neurotoxicity as a Prognostic Factor in Patients with Metastatic Breast Cancer Treated with Ixabepilone as a First-Line Therapy

By  

Oncology, Vol. 88, Iss. 3, 2014-11 ,pp. : 180-188

Karger

Access to resources Recommend Favorite

Triple-negative breast cancer

By Bartsch Rupert  

Wiener Medizinische Wochenschrift, Vol. 160, Iss. 7-8, 2010-04 ,pp. : 174-181

Springer Publishing Company

Access to resources Recommend Favorite

An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

By  

Oncology, Vol. 84, Iss. 5, 2013-03 ,pp. : 299-304

Karger

Access to resources Recommend Favorite